We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: liver fibrosis
MedXY News
EnglishTag

liver fibrosis

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Subclinical Liver Disease as a Silent Driver of Cardiovascular Risk: Insights from a Large-Scale Prospective Study
Cardiologyhepatic steatosiscardiovascular risk

Subclinical Liver Disease as a Silent Driver of Cardiovascular Risk: Insights from a Large-Scale Prospective Study

By MedXY|Sep 15, 2026

Subclinical liver disease, marked by steatosis, fibrosis, and functional impairment, independently and synergistically increases cardiovascular disease risk. Incorporating non-invasive liver biomarkers could enhance CVD risk prediction and

Cardiovascular-Kidney-Metabolic Syndrome and Its Impact on Liver Fibrosis Progression and Liver-Related Events in MASLD
GastroenterologyMASLD
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
cardiovascular-kidney-metabolic syndrome

Cardiovascular-Kidney-Metabolic Syndrome and Its Impact on Liver Fibrosis Progression and Liver-Related Events in MASLD

By MedXY|Aug 14, 2026

This article reviews evidence linking cardiovascular-kidney-metabolic syndrome stages to liver fibrosis severity, progression, and liver-related events in metabolic dysfunction-associated steatotic liver disease (MASLD). Higher CKM stages i

Disentangling Weight Loss-Dependent and Independent Effects of Survodutide on Liver Outcomes in MASH: Insights from a Phase 2 Mediation Analysis
Diabetes & EndocrinologyMASHMediation Analysis

Disentangling Weight Loss-Dependent and Independent Effects of Survodutide on Liver Outcomes in MASH: Insights from a Phase 2 Mediation Analysis

By MedXY|Aug 4, 2026

This mediation analysis of a phase 2 MASH trial reveals that survodutide improves liver inflammation and fibrosis predominantly through weight-independent mechanisms, highlighting a potential direct hepatic effect beyond weight reduction.

Diabetes & EndocrinologyMASLDpFIB score

pFIB Scores for Pediatric MASLD Fibrosis Linked to Risk of Youth-Onset Type 2 Diabetes in Children with Obesity

By MedXY|Jul 25, 2026

A liver fibrosis risk score (pFIB-6) identifies children with obesity at markedly increased short-term risk of type 2 diabetes, offering a potential tool for early risk stratification.

Global Variability in Non-Invasive Testing Accuracy for MASLD: Key Findings from the G-MASLD Study
GastroenterologyGlobal studyliver fibrosis

Global Variability in Non-Invasive Testing Accuracy for MASLD: Key Findings from the G-MASLD Study

By MedXY|Jul 16, 2026

The G-MASLD study evaluated the diagnostic accuracy of non-invasive fibrosis tests across 41 countries, revealing regional variability and identifying Agile-3+ and Agile-4 as the most accurate for advanced fibrosis and cirrhosis in MASLD pa

Unraveling Hepatitis B-Induced Liver Fibrosis: The Critical Role of Pyruvate, PPARα, and Reactive Oxygen Species
GastroenterologyHBVliver fibrosis

Unraveling Hepatitis B-Induced Liver Fibrosis: The Critical Role of Pyruvate, PPARα, and Reactive Oxygen Species

By MedXY|Jul 10, 2026

This article explores the mechanism by which HBV induces liver fibrosis through pyruvate-dependent ROS production and PPARα inhibition, highlighting novel therapeutic targets for chronic hepatitis B management.

Decoding Liver Fibrosis in MASLD: AI-Derived Collagen Phenotypes Enhance Molecular and Clinical Insights
Gastroenterologyartificial intelligencecollagen deposition phenotypes

Decoding Liver Fibrosis in MASLD: AI-Derived Collagen Phenotypes Enhance Molecular and Clinical Insights

By MedXY|Jun 25, 2026

This article explores a novel AI framework that identifies distinct collagen deposition patterns in MASLD, offering improved molecular specificity and prognostic value beyond traditional fibrosis assessments.

Validated Early Detection Metrics Could Narrow Liver Fibrosis Screening Without Losing Clinical Signal
Gastroenterologyliver fibrosispublic health

Validated Early Detection Metrics Could Narrow Liver Fibrosis Screening Without Losing Clinical Signal

By MedXY|Jun 19, 2026

A validation study suggests current liver fibrosis screening criteria are too broad. A refined risk-based approach reduced eligibility from 60–76% to 10–22% of adults while improving the yield of elevated liver stiffness and predicting futu

Validating the Virtual Biopsy: Noninvasive Surrogate Endpoints for Disease Progression and Treatment Efficacy in MASH
Clinical Updatesliver fibrosisMASH

Validating the Virtual Biopsy: Noninvasive Surrogate Endpoints for Disease Progression and Treatment Efficacy in MASH

By MedXY|Apr 2, 2026

This review synthesizes the evolving landscape of noninvasive tests (NITs) in MASH, detailing their role as surrogate endpoints for adverse outcomes and therapeutic response based on recent clinical trials and meta-analyses.

Beyond the Backpressure: Targeting the Integrin αV-YAP-CTGF Axis to Halt Fibrosis in Congestive Hepatopathy
CardiologyCongestive Hepatopathyliver fibrosis

Beyond the Backpressure: Targeting the Integrin αV-YAP-CTGF Axis to Halt Fibrosis in Congestive Hepatopathy

By MedXY|Mar 31, 2026

This study identifies the integrin αV-YAP-CTGF axis in liver sinusoidal endothelial cells as a primary driver of fibrosis and carcinogenesis in congestive hepatopathy. By targeting this mechanosensitive pathway, researchers demonstrated a s

Targeting the Integrin αV-YAP-CTGF Axis: A New Frontier in Treating Congestive Hepatopathy and Liver Carcinogenesis
CardiologyCongestive Hepatopathyliver fibrosis

Targeting the Integrin αV-YAP-CTGF Axis: A New Frontier in Treating Congestive Hepatopathy and Liver Carcinogenesis

By MedXY|Mar 28, 2026

Researchers have identified a mechanosensitive signaling pathway in liver sinusoidal endothelial cells that drives fibrosis and cancer in response to chronic congestion, offering a new therapeutic target for heart-failure-related liver dise

From Pressure to Cancer: Unveiling the Integrin αV-YAP-CTGF Axis as a Therapeutic Target in Congestive Hepatopathy
CardiologyCongestive Hepatopathyliver fibrosis

From Pressure to Cancer: Unveiling the Integrin αV-YAP-CTGF Axis as a Therapeutic Target in Congestive Hepatopathy

By MedXY|Mar 28, 2026

Researchers have identified a novel signaling pathway in liver sinusoidal endothelial cells (LSECs) that drives fibrosis and liver cancer in congestive hepatopathy. The study highlights the Integrin αV-YAP-CTGF axis as a critical mechanism

Mechanotransduction in Congestive Hepatopathy: The Integrin αV-YAP-CTGF Axis as a Driver of Fibrosis and Carcinogenesis
Clinical UpdatesCongestive Hepatopathyliver fibrosis

Mechanotransduction in Congestive Hepatopathy: The Integrin αV-YAP-CTGF Axis as a Driver of Fibrosis and Carcinogenesis

By MedXY|Mar 18, 2026

This review synthesizes recent findings on how mechanical stress in congestive hepatopathy activates the Integrin αV-YAP-CTGF pathway in liver sinusoidal endothelial cells, leading to fibrosis and liver cancer.

Metabolic Synergy: How Obesity and Diabetes Amplify Liver Disease Risk in Alpha-1 Antitrypsin Deficiency
GastroenterologyHepatologyliver fibrosis

Metabolic Synergy: How Obesity and Diabetes Amplify Liver Disease Risk in Alpha-1 Antitrypsin Deficiency

By MedXY|Mar 13, 2026

A large-scale longitudinal study reveals that obesity and diabetes synergistically amplify the risk of advanced liver disease in individuals with Alpha-1 Antitrypsin Deficiency (AATD), while also identifying a complex relationship between b

Nearly 40 Percent of Indian Adults Impacted by MASLD: New Evidence from the Phenome India Cohort
GastroenterologyHepatologyliver fibrosis

Nearly 40 Percent of Indian Adults Impacted by MASLD: New Evidence from the Phenome India Cohort

By MedXY|Feb 17, 2026

The Phenome India study identifies a 38.9% age-adjusted prevalence **Constructing the JSON Object** Now, I’m carefully constructing the JSON object, which needs to be a valid, parseable string. I’m focusing on incorporating the

Monthly Efimosfermin Alfa Demonstrates Safety and Tolerability in MASH-Related Fibrosis: Insights from a Phase 2 Trial
Gastroenterologyefimosfermin alfaliver fibrosis

Monthly Efimosfermin Alfa Demonstrates Safety and Tolerability in MASH-Related Fibrosis: Insights from a Phase 2 Trial

By MedXY|Feb 16, 2026

The Phase 2 trial of efimosfermin alfa (BOS-580) shows that once-monthly dosing is safe and well-tolerated in patients with MASH and F2/F3 fibrosis, supporting its continued clinical development as a potential liver-targeted therapy.

Tirzepatide and the Future of MASH Treatment: Insights from the SYNERGY-NASH Trial
Diabetes & Endocrinologyliver fibrosisMASH

Tirzepatide and the Future of MASH Treatment: Insights from the SYNERGY-NASH Trial

By MedXY|Jan 10, 2026

The SYNERGY-NASH trial demonstrates that Tirzepatide significantly improves MASH resolution and liver fibrosis. This effect is driven by substantial weight loss, improved glycemic control, and liver fat normalization, highlighting a transfo

GLP‑1 Receptor Agonists Associated with Lower Fibrosis Progression in MASLD and T2DM: Target‑Trial Emulation of Real‑World Data
Diabetes & EndocrinologyGLP-1RAliver fibrosis

GLP‑1 Receptor Agonists Associated with Lower Fibrosis Progression in MASLD and T2DM: Target‑Trial Emulation of Real‑World Data

By MedXY|Nov 23, 2025

A target-trial emulation of 4,476 matched T2DM patients with early MASLD found GLP-1RA use was associated with a 25% lower hazard of progression to high-risk FIB‑4 versus DPP‑4i (HR 0.75); no difference was seen for hard liver outcomes.

SGLT2 Inhibitors Linked to Lower Fibrosis Progression than DPP‑4 Inhibitors in MASLD with T2DM: Target‑Trial Emulation of Real‑World Cohorts
Diabetes & Endocrinologyliver fibrosisMASLD

SGLT2 Inhibitors Linked to Lower Fibrosis Progression than DPP‑4 Inhibitors in MASLD with T2DM: Target‑Trial Emulation of Real‑World Cohorts

By MedXY|Nov 17, 2025

A multicenter target‑trial emulation found SGLT2 inhibitor initiation was associated with a 22% lower risk of progression to advanced fibrosis (confirmed FIB‑4 >2.67) versus DPP‑4 inhibitors in adults with MASLD and T2DM and low‑to‑inter

Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions
Diabetes & Endocrinologyliver fibrosisMASH

Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions

By MedXY|Nov 14, 2025

Pemvidutide, a dual GLP‑1/glucagon receptor agonist, reduced liver fat markedly and produced small but statistically significant reductions in AI‑quantified fibrosis over 24 weeks in phase 2 studies, but longer trials with clinical endpoint

1 / 2
12
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities